TBPMF News and Press, Tetra Bio-Pharma Inc From 04/29/21

NEW YORK, April 29, 2021 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, is highlighting the latest CEO comments and news from companies recently presenting at its highly acclaimed NEXT SUPER STOCK livestream investor conferences, and investor ȁ...

Tetra plans for global commercialization of QIXLEEF OTTAWA, ON / ACCESSWIRE / April 28, 2021 / Tetra Bio-Pharma Inc. (" Tetra " or the " Company ") (TSX:TBP) (OTCQB:TBPMF) (FRA:JAM1) , a leader in cannabinoid-derived drug discovery and development announced today that it has submit...

Tetra Bio-Pharma (TBPMF) announced that it has shipped the investigational therapy Qixleef to the U.S. for the initiation of a Phase 2 proof-of-concept trial in the management of breakthrough cancer pain (BTcP).After completing the production of Qixleef, the company has also obtaine...

First clinical study to assess cannabis as an alternative to morphine Tetra completes manufacturing of QIXLEEF clinical trial drug for REBORN1 trial Export permit received from Health Canada for immediate shipping to USA OTTAWA, ON / ACCESSWIRE / April 23, 2021 / Tetra Bio-...

Tetra strengthens its intellectual property portfolio Approximately 12% of women may have early symptoms of Interstitial Cystitis OTTAWA, ON / ACCESSWIRE / April 15, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") ( TSX:TBP )( OTCQB:TBPMF )( FRA:JAM1 ), a biopharmaceuti...

Tetra Bio-Pharma (TBPMF) has advanced the REDUVO soft gel capsules New Drug Submission ((NDS)) file by responding to a request for more information from Health Canada. On April 9, Tetra submitted all the requested information to Health Canada. This will now allow the regulatory agency to...

REDUVO would have Canada's only Drug Identification Number for a THC-based prescription drug The addressable market is estimated to be $80M CDN by 2022 OTTAWA, ON / ACCESSWIRE / April 14, 2021 / Tetra Bio-Pharma Inc . (" Tetra " or the " Company ") (TSX:TBP) (OTCQB:TBPMF) (FR...

The FDA has favorably reviewed the preclinical data package and clinical development plan of Tetra Bio-Pharma's (TBPMF) ARDS-003 to treat COVID-19. The Agency agreed with the animal toxicology and safety data to ensure that ARDS-003 is safe for human use, and approved the sample size, sa...

FDA acknowledged that the preclinical safety data are acceptable to file an Investigational New Drug Application (IND) aimed at treating hospitalized COVID-19 patients at risk of developing ARDS OTTAWA, ON / ACCESSWIRE / April 5, 2021 / Tetra Bio-Pharma Inc . (" Tetra " or the " Comp...

Tetra Bio-Pharma Inc. receives a Notice of Compliant rated inspection to distribute pharmaceuticals Key milestone in the development path to commercialization of Reduvo OTTAWA, ON / ACCESSWIRE / April 1, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP) (OTCQB...